These observations were consistent with original phenotyping results in CD40L-/- mice (31). Astragaloside A assessed during a 100-day follow-up period. Results and Discussion Administering CD40L mAb as monotherapy at the time of transplantation significantly prolonged heart allograft survival but did not further improve the outcome when given in addition to chronic CTLA4-Ig therapy (which prolongs graft survival to a median of 22 days). Likewise, chronic CD40L mAb therapy (0.5mg) Astragaloside A combined with perioperative CTLA4-Ig led to rejection in a proportion of mice and extensive histological damage, despite abrogating DSA formation. Only the permanent interruption of CD40-CD40L signaling by using CD40L-/- recipient mice or by chronic CD40L administration synergized with chronic CTLA4-Ig to achieve long-term allograft survival with preserved histological graft integrity in all recipients without DSA formation. The combination of -CD40L and CTLA4-Ig works most effectively when both therapeutics are administered chronically. Keywords: costimulation blockade, CTLA4Ig, CD40L blockade, murine cardiac allotransplant, transplantation Introduction.? The advent of calcineurin inhibitors (CNI) in the 1980s established transplantation as the treatment of choice for end-stage organ failure in heart, lung, liver and kidney diseases. Subsequent improvements in surgical techniques and drug development resulted in an excellent short-term graft survival, while long term allograft survival in solid organ transplantation still remains unsatisfactory (1, 2). Apart from immune-mediated damage that contributes to chronic graft failure, CNIs exhibit direct nephrotoxicity (3). These adverse events, as well as an improved understanding of T cell activation have led to the conceptualized development of a new immunosuppressive drug class, namely costimulation blockers (4, 5). Belatacept, which is a fusion protein combining the mutated extracellular part of cytotoxic T-lymphocyte-associated protein 4 (CTLA4) with a human constant region fragment of IgG1, was intentionally designed to block the CD28 pathway and has been approved for kidney transplantation (6). Belatacept improved overall Rabbit Polyclonal to SIRT2 patient and graft survival (7), preserved kidney function better than cyclosporine A, and prevented donor-specific IgG antibody formation more efficiently (8C10). However, belatacept is also associated with an increased risk of acute cellular rejection episodes, especially in the first year following transplantation (7, 11). Although these rejection episodes seemed to have no detrimental effect on long term outcome (10), they are nevertheless cause of concern and their avoidance through optimized drug combinations could decrease the number of hospitalization episodes early after transplantation. In order to refine treatment strategies and test potential induction therapies, we have recently developed a murine vascularized heterotopic heart transplant regimen for chronic CTLA4-Ig monotherapy modeled after the clinically approved dosing regimen. In this model, C57BL/6 recipients of a fully mismatched BALB/c cardiac allograft rejected the transplanted heart with a median Astragaloside A survival time (MST) of 60 days, with approximately 10 percent of the grafts surviving long-term (100 days) but showing extensive immune-mediated graft damage at the end of follow-up (12). Additionally, all recipients eventually developed donor specific antibodies (DSA) and showed early signs of acute rejection as early as 11 days after transplantation. We could demonstrate as proof-of-concept, that a 5-fold increase in dosing intensity (from 0.25mg to 1 1.25mg) significantly reduces, and a 25-fold increase (from 0.25mg to 6.25mg per time point) completely inhibits IgG DSA formation, leads to long-term graft survival and mostly abrogates histological signs of cellular rejection in all mice. In the clinic, however, an increase in dosing intensity by that order of magnitude is not an option (11). It is also very unlikely that a higher dose will be approved after the rate of acute rejection was slightly increased in the.